Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
23/4 15:53
Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023....